In an adult or adolescent with dyspnea, chronic cough, wheeze, or suspected obstructive or restrictive lung disease, when and how should spirometry be performed and how are the results interpreted?

Spirometry: When to Perform and How to Interpret

Spirometry should be performed in any adult or adolescent over age 40 with dyspnea, chronic cough, wheeze, or risk factor exposure (smoking, occupational exposures), and post-bronchodilator spirometry with FEV1/FVC <0.7 is required to confirm obstructive lung disease, while pre-bronchodilator testing can rule out COPD if the ratio is ≥0.7. 1

When to Perform Spirometry

Key Clinical Indicators

Perform spirometry if any of these are present in individuals over 40 years 2:

• Dyspnea that is progressive, worse with exercise, or persistent
• Chronic cough (may be intermittent or unproductive)
• Chronic sputum production of any pattern
• Recurrent wheeze
• Recurrent lower respiratory tract infections
• Risk factor exposure: tobacco smoke, occupational dusts/vapors/fumes/gases, biomass fuel smoke
• Family history of COPD or childhood respiratory factors

For asthma evaluation, spirometry is essential in patients aged 5 years and older presenting with recurrent episodes of cough and wheezing, as history and physical examination alone are unreliable for diagnosis 3.

How to Perform Spirometry

Pre-Bronchodilator Testing

Start with pre-bronchodilator spirometry as the initial screening test 1. If pre-BD FEV1/FVC ≥0.7, COPD is ruled out in most cases and no further testing is needed, reducing clinical workload. The exception is when clinical suspicion remains very high despite normal pre-BD values.

Post-Bronchodilator Testing

Post-BD spirometry is mandatory to confirm the diagnosis when pre-BD FEV1/FVC <0.7 2, 1. This approach:

• Prevents overdiagnosis by identifying "flow responders" whose ratio normalizes after bronchodilation
• Identifies "volume responders" with gas trapping who may have normal pre-BD ratios but abnormal post-BD ratios
• Provides the definitive diagnostic criterion

Bronchodilator Administration

Administer an adequate dose of at least one short-acting inhaled bronchodilator 2:

• Salbutamol (albuterol): 400 mcg via MDI with spacer (4 puffs of 100 mcg each) provides 10-20% lung deposition 4
• Ipratropium bromide: 160 mcg total dose 4
• Wait 10-15 minutes after short-acting beta-agonist or 30-45 minutes after anticholinergic before repeat testing

Quality Control Requirements

Obtain at least 3 acceptable maneuvers with 4, 5:

• Rapid rise to peak flow on flow-volume curve
• Smooth descending limb without cough or glottic closure
• Grade A quality: ≥3 acceptable tests with repeatability within 0.100 L or 10% (whichever is greater)
• Grade B quality: ≥2 acceptable tests with same repeatability criteria
• Grades A, B, or C are usable for interpretation

Interpretation of Results

Diagnostic Algorithm

Step 1: Assess FEV1/FVC Ratio Post-Bronchodilator

• FEV1/FVC <0.7: Confirms airflow obstruction (COPD or asthma) 2, 6
• FEV1/FVC ≥0.7: Rules out obstructive disease in most cases

Step 2: If Post-BD FEV1/FVC is 0.60-0.80 Repeat spirometry on a separate occasion (within 3-6 months) to confirm the diagnosis, as biological variation may change the ratio 1. If initial post-BD FEV1/FVC <0.60, repeat testing is unnecessary as spontaneous normalization is very unlikely.

Step 3: Assess Reversibility (for obstructive pattern) Significant bronchodilator response in adults 3, 7:

• FEV1 or FVC improvement ≥12% AND ≥0.2 L (200 mL)
• In children/adolescents 5-18 years: >12% improvement alone

Greater reversibility suggests asthma, though COPD patients can also show significant responses.

Step 4: Severity Classification (if obstructive) Based on post-BD FEV1 % predicted 2, 6:

• Mild: FEV1 ≥80% predicted
• Moderate: FEV1 50-80% predicted
• Severe: FEV1 30-50% predicted
• Very severe: FEV1 <30% predicted

Step 5: Assess for Restriction

• Low FVC (<5th percentile or <80% predicted in children) with normal FEV1/FVC suggests restrictive pattern 7
• Requires lung volume measurements to confirm true restriction

Critical Pitfalls to Avoid

"Flow Responders" (Pre-BD obstruction → Post-BD normal): These individuals with pre-BD FEV1/FVC <0.7 that normalizes to ≥0.7 post-BD have nearly 50% likelihood of developing persistent post-BD obstruction during follow-up 1. Do not dismiss these patients—schedule repeat spirometry in 3-6 months, especially if they continue smoking or have ratios close to 0.7.

"Volume Responders" (Pre-BD normal → Post-BD obstruction): Gas trapping reduces FVC more than FEV1, falsely normalizing the pre-BD ratio. Post-BD testing unmasks obstruction by relieving gas trapping and increasing FVC proportionally more than FEV1, dropping the ratio below 0.7 1. This is more common with lower baseline FEV1 (<80% predicted). Always perform post-BD testing when clinical suspicion is high despite normal pre-BD values.

Fixed Ratio vs. Lower Limit of Normal: The fixed ratio of 0.7 may overdiagnose COPD in elderly patients and underdiagnose in younger adults <45 years 2. However, GOLD prioritizes the fixed ratio for diagnostic simplicity and consistency, as spirometry is only one component of clinical diagnosis alongside symptoms and risk factors.

Additional Testing Considerations

When spirometry is normal but asthma suspected: Consider bronchoprovocation testing with methacholine, histamine, cold air, or exercise challenge 3. A negative test is more helpful to rule out asthma than a positive test is to confirm it.

Pediatric modifications 8:

• Children 2-6 years: Accept shorter expiratory times if reproducible
• Repeatability criteria: within 0.150 L for ages 2-6
• Forced oscillation or interrupter resistance may be used in children as young as 3 years